Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp209 | Diabetes: Pharmacotherapy | ECE2019

Efficacy and tolerability of dulaglutide in patients with type 2 diabetes: Experience on a secondary Hospital

Lazaro Paloma Gonzalez , Pascual Cristina Contreras , del Val Zaballos Florentino , Fernandez Julia Silva , Alfonso Francisco Javier Gomez , Arroyo Belvis Torres , de Agredos Alvaro Garcia Manzanares Vazquez , Garcia Ines Gomez

Introduction: Dulaglutide (Trulicity®) is a long-acting GLP-1 agonist that received US Food and Drug Administration (FDA) approval in 2014. Dulaglutide is a large sized molecule, which limits its renal clearance. This allows for once weekly dosing; which might improve patient compliance significantly. Extensive Phase III study data have been published with regard to dulaglutide, much of which was part of the AWARD studies, which provide evidence for its use in ...

ea0049ep11 | Adrenal cortex (to include Cushing's) | ECE2017

Posterior reversible encephalopathy syndrome (PRES) in a patient with primary aldosteronism

Silva-Fernandez Julia , Val-Zaballos Florentino Del , Gomez-Alfonso Francisco Javier , Gonzalez-Lazaro Paloma , Torres-Arroyo Belvis , Garcia-Ruiz Rafael , de Agredos Alvaro Garcia-Manzanares Vazquez , Lopez-Iglesias Maria , Gomez-Garcia Ines

Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder characterized by varied neurological symptoms. There are two leading theories regarding the pathophysiology: hypertension crisis and endothelial dysfunction.Case reportWe report the case of a 42-year-old patient with history of hypertension. She presented to the emergency department with headache and bilateral loss of vision. She described one previous e...

ea0049ep955 | Pituitary - Clinical | ECE2017

Gambling and cabergoline

Silva-Fernandez Julia , Gomez-Alfonso Francisco Javier , Del Val-Zaballos Florentino , Torres-Arroyo Belvis , Gonzalez-Lazaro Paloma , de Agredos Alvaro Garcia-Manzanares Vazquez , Lopez-Iglesias Maria , Garcia-Ruiz Rafael , Gomez-Garcia Ines

Introduction: A link between Dopamine agonists and development of impulse control disorders is well recognized in the field of neurology. A similar finding in endocrine patients is emerging.Case report: We report the case of a 38-year-old man with pathological addiction to gambling associated with low dose cabergoline treatment for a mixed growth hormone (GH) and prolactin (PRL)-secreting pituitary adenoma. At the age of 29 he ...